Key Highlights
- Tempest Therapeutics (NASDAQ:TPST) indicated at USD 0.4050 pre-market on Tuesday, November 10, 2026, up 12.06% from a calculated prior close of USD 0.3614 set on Monday, November 9.
- Published market data shows a market Capitalization of USD 7.23 million on 20.00 million shares, with a 52-week range of USD 0.36 to USD 9.75.
- Pre-market Liquidity is thin: the quote page showed 5,451 shares traded against an average Volume of 2.55 million, or about 0.21% of a normal day.
- No catalyst was identified in published coverage for the move, and the last cash figure on the quote page was only USD 779,000, so the risk of dilution is high.
What Moved Tempest Therapeutics Pre-Market (+12.06%)
The pre-market indication of USD 0.4050 on Tuesday, November 10, 2026 is a gain of USD 0.0436 per share, calculated from the screener change of 12.06% and a prior close of USD 0.3614. The published quote page rounds that prior close to USD 0.36, which is also the bottom of the stock's 52-week range. At USD 0.4050 the shares sit 95.8% below the 52-week high of USD 9.75 and 12.5% above the low, both calculated. On 20.00 million shares the indicated value is about USD 8.1 million, calculated, against the USD 7.23 million market capitalization on the quote page. Two searches found no company release, filing or published coverage dated November 9 or November 10, 2026 that explains the move, so no catalyst is identified in published coverage.
The Rationale: No Catalyst Identified, and What Usually Drives Such Moves
With no news found, the move may be technical. General context: a stock trading far below USD 1.00 can bounce when short sellers cover, when a few retail buyers hit a thin order book, or when a sympathy move follows a peer in oncology. Nasdaq's general rule requires a minimum bid of USD 1.00, and a stock that closes below it for 30 consecutive Business days receives a deficiency notice and a 180-day compliance period, which often leads to a reverse split. Biotechs at this size also commonly raise cash through registered direct offerings, which add shares and can reverse a bounce. The company's recent filings include a 10-Q for the quarter ended June 30, 2026, and one published summary of that period described a liquidity squeeze alongside clinical progress. Those are background items, not an explanation for November 10.
Valuation, Liquidity, 52-Week Range and Risks
The USD 7.23 million market capitalization is small against the USD 779,000 of cash and short-term investments shown on the quote page, so the Balance Sheet figure may be stale and should be checked against the latest 10-Q. Pre-market trading is thin: 5,451 shares is a few thousand dollars of turnover, and spreads can be wide, so a small number of trades can move the indication by several points. The stock ended its 52-week range at the low of USD 0.36, which means a 12.06% bounce still leaves it near the bottom. Key risks are dilution from new shares, a Nasdaq bid-price deficiency, financing terms that discount the stock, and Reversal at the open. Nothing here implies the move will continue.
Where Things Stand
Tempest Therapeutics (NASDAQ:TPST) is indicated 12.06% higher pre-market because of an unidentified trigger: no company news was found for November 9 or 10, 2026. The shares are at USD 0.4050, still 95.8% below the USD 9.75 high, with a market capitalization of USD 7.23 million and 20.00 million shares. Thin volume of 5,451 shares versus 2.55 million on average means the indication is fragile. Watch the 9:30 a.m. ET open, the next filing and any financing announcement.






Please wait processing your request...